173 related articles for article (PubMed ID: 30352297)
1. Vaccine programme stakeholder perspectives on a hypothetical single-dose human papillomavirus (HPV) vaccine schedule in low and middle-income countries.
Gallagher KE; Kelly H; Cocks N; Dixon S; Mounier-Jack S; Howard N; Watson-Jones D
Papillomavirus Res; 2018 Dec; 6():33-40. PubMed ID: 30352297
[TBL] [Abstract][Full Text] [Related]
2. Experiences and lessons learned from 29 HPV vaccination programs implemented in 19 low and middle-income countries, 2009-2014.
Ladner J; Besson MH; Audureau E; Rodrigues M; Saba J
BMC Health Serv Res; 2016 Oct; 16(1):575. PubMed ID: 27737666
[TBL] [Abstract][Full Text] [Related]
3. Human papillomavirus (HPV) vaccine coverage achievements in low and middle-income countries 2007-2016.
Gallagher KE; Howard N; Kabakama S; Mounier-Jack S; Burchett HED; LaMontagne DS; Watson-Jones D
Papillomavirus Res; 2017 Dec; 4():72-78. PubMed ID: 29179873
[TBL] [Abstract][Full Text] [Related]
4. Options for design of real-world impact studies of single-dose vaccine schedules.
Franceschi S; Clifford GM; Baussano I
Vaccine; 2018 Aug; 36(32 Pt A):4816-4822. PubMed ID: 29571973
[TBL] [Abstract][Full Text] [Related]
5. Inconclusive evidence for non-inferior immunogenicity of two- compared with three-dose HPV immunization schedules in preadolescent girls: A systematic review and meta-analysis.
Donken R; Knol MJ; Bogaards JA; van der Klis FR; Meijer CJ; de Melker HE
J Infect; 2015 Jul; 71(1):61-73. PubMed ID: 25709084
[TBL] [Abstract][Full Text] [Related]
6. Costs of introducing and delivering HPV vaccines in low and lower middle income countries: inputs for GAVI policy on introduction grant support to countries.
Levin A; Wang SA; Levin C; Tsu V; Hutubessy R
PLoS One; 2014; 9(6):e101114. PubMed ID: 24968002
[TBL] [Abstract][Full Text] [Related]
7. Introduction of human papillomavirus (HPV) vaccination into national immunisation schedules in Europe: Results of the VENICE 2007 survey.
King LA; Lévy-Bruhl D; O'Flanagan D; Bacci S; Lopalco PL; Kudjawu Y; Salmaso S;
Euro Surveill; 2008 Aug; 13(33):. PubMed ID: 18761891
[TBL] [Abstract][Full Text] [Related]
8. Optimal human papillomavirus vaccination strategies to prevent cervical cancer in low-income and middle-income countries in the context of limited resources: a mathematical modelling analysis.
Drolet M; Laprise JF; Martin D; Jit M; Bénard É; Gingras G; Boily MC; Alary M; Baussano I; Hutubessy R; Brisson M
Lancet Infect Dis; 2021 Nov; 21(11):1598-1610. PubMed ID: 34245682
[TBL] [Abstract][Full Text] [Related]
9. Overcoming barriers to HPV vaccination: non-inferiority of antibody response to human papillomavirus 16/18 vaccine in adolescents vaccinated with a two-dose vs. a three-dose schedule at 21 months.
Lazcano-Ponce E; Stanley M; Muñoz N; Torres L; Cruz-Valdez A; Salmerón J; Rojas R; Herrero R; Hernández-Ávila M
Vaccine; 2014 Feb; 32(6):725-32. PubMed ID: 24355090
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and reactogenicity of alternative schedules of HPV vaccine in Vietnam: a cluster randomized noninferiority trial.
Neuzil KM; Canh DG; Thiem VD; Janmohamed A; Huong VM; Tang Y; Diep NT; Tsu V; LaMontagne DS
JAMA; 2011 Apr; 305(14):1424-31. PubMed ID: 21486975
[TBL] [Abstract][Full Text] [Related]
11. Alternative HPV vaccination schedules in Latin America.
Robles C; Hernández ML; Almonte M
Salud Publica Mex; 2018; 60(6):693-702. PubMed ID: 30699274
[TBL] [Abstract][Full Text] [Related]
12. The current state of introduction of human papillomavirus vaccination into national immunisation schedules in Europe: first results of the VENICE2 2010 survey.
Dorleans F; Giambi C; Dematte L; Cotter S; Stefanoff P; Mereckiene J; O'Flanagan D; Lopalco PL; D'Ancona F; Levy-Bruhl D;
Euro Surveill; 2010 Nov; 15(47):. PubMed ID: 21144444
[TBL] [Abstract][Full Text] [Related]
13. What works for human papillomavirus vaccine introduction in low and middle-income countries?
Howard N; Gallagher KE; Mounier-Jack S; Burchett HED; Kabakama S; LaMontagne DS; Watson-Jones D
Papillomavirus Res; 2017 Dec; 4():22-25. PubMed ID: 29179865
[TBL] [Abstract][Full Text] [Related]
14. Human papillomavirus vaccine introduction--the first five years.
Markowitz LE; Tsu V; Deeks SL; Cubie H; Wang SA; Vicari AS; Brotherton JM
Vaccine; 2012 Nov; 30 Suppl 5():F139-48. PubMed ID: 23199957
[TBL] [Abstract][Full Text] [Related]
15. Impact of partial bivalent HPV vaccination on vaccine-type infection: a population-based analysis.
Cuschieri K; Kavanagh K; Moore C; Bhatia R; Love J; Pollock KG
Br J Cancer; 2016 May; 114(11):1261-4. PubMed ID: 27115467
[TBL] [Abstract][Full Text] [Related]
16. Scientific evidence supporting recommendations on the use of the 9-valent HPV vaccine in a 2-dose vaccine schedule in Australia.
Wnukowski-Mtonga P; Jayasinghe S; Chiu C; Macartney K; Brotherton J; Donovan B; Hall M; Smith DW; Peterson K; Campbell-Lloyd S; Selvey C; Giles M; Kaldor J; Marshall H;
Commun Dis Intell (2018); 2020 Apr; 44():. PubMed ID: 32299331
[TBL] [Abstract][Full Text] [Related]
17. Value and effectiveness of National Immunization Technical Advisory Groups in low- and middle-income countries: a qualitative study of global and national perspectives.
Bell S; Blanchard L; Walls H; Mounier-Jack S; Howard N
Health Policy Plan; 2019 May; 34(4):271-281. PubMed ID: 31074778
[TBL] [Abstract][Full Text] [Related]
18. Current issues facing the introduction of human papillomavirus vaccine in China and future prospects.
Wong LP; Han L; Li H; Zhao J; Zhao Q; Zimet GD
Hum Vaccin Immunother; 2019; 15(7-8):1533-1540. PubMed ID: 31017500
[TBL] [Abstract][Full Text] [Related]
19. Country recommendations on the inclusion of HPV vaccines in national immunization programmes among high-income countries, June 2006-January 2008.
Koulova A; Tsui J; Irwin K; Van Damme P; Biellik R; Aguado MT
Vaccine; 2008 Dec; 26(51):6529-41. PubMed ID: 18805453
[TBL] [Abstract][Full Text] [Related]
20. Challenges and lessons from a school-based human papillomavirus (HPV) vaccination program for adolescent girls in a rural Nigerian community.
Egbon M; Ojo T; Aliyu A; Bagudu ZS
BMC Public Health; 2022 Aug; 22(1):1611. PubMed ID: 36002832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
